The Role of the Private Vet

Slides:



Advertisements
Similar presentations
Henry Ottilie Institut für Pharmakologie, Pharmazie und Toxikologie,
Advertisements

Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Municipality of Sofia Stray Dogs Program Maria Boyadjiyska Deputy Mayor April 10, 2014 Brussels.
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
Basic Pharmacovigilance Training
Treatment Plan.
 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Isah, Ambrose Ohumagho (1); Pal, Shanthi (2); Olsson, Sten (3)
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
INTRODUCTION TO TOXICOLOGY SIDNEY GREEN, PH.D. DEPARTMENT OF PHARMACOLOGY COLLEGE OF MEDICINE HOWARD UNIVERISTY.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.
Is the conscientious explicit and judicious use of current best evidence in making decision about the care of the individual patient (Dr. David Sackett)
Signal identification and development I.Ralph Edwards.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
Minimum requirements for Pharmacovigilance in countries.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
Istanbul April 2011 Dr Joe Collins MVB PhD CBiol FSB MRCVS CertEP CertVR VMPs: - Availability - MUMS - Cascade.
In the Best Interests of the Public Health... Janice Soreth, M.D. Acting Director Division of Anti-Infective Drug Products CDER/FDA.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
TAIEX Workshop on the Implementation of EU Pharmacovigilance Legislation - BELGRADE CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser.
1 Pharmacovigilance & the New National Adverse Drug Reaction (ADR) Reporting System Michael Bonett, Quality Assessor Post-Licensing Directorate Medicines.
The Adverse Experience Reporting Program (AERP). Industrial and domestic chemicals – NICNAS (National Industrial Chemicals Notification and Assessment.
1 PHARMACOVIGILANCE & THE NATIONAL ADVERSE DRUG REACTION (ADR) REPORTING SYSTEM Sarah Spiteri Post-Licensing Directorate Medicines Authority.
Waiving TABST for vaccines Argentina: Not an allowed procedure today Require batch safety tests in laboratory animals, repeated by authorities Currently.
RAC Regulatory Affairs Certification
CLINICAL TRIALS.
Taxonomy of Strategies
Off-label Use.
A capacity building programme for patient representatives
Detection & monitoring of ADR
Efficacy and Safety of Medicines
Assoc. Prof. Martin Valis, M.D., Ph.D.
Risk Communication in Medicines
FDA Perspective on Cardiovascular Device Development
Community Participation in Research
8. Causality assessment:
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Within Trial Decisions: Unblinding and Termination
Clinical Trials Medical Interventions
US Prescribers and Biosimilars Naming
Jennifer S. Novia INFO 643 March 6, 2011
Pharmacovigilance in clinical trials
عناوین برنامه واهداف ADR ونقش آن در ایمنی دارویی محاسبات دارویی
Quality Assurance and Safety of Medicines
TAIEX, Istanbul, April 19th, 2011
The role of the HPRA in the authorisation of veterinary medicinal products The role of the Health Products Regulatory Authority in the authorisation of.
Clinical Trials.
Pharmacovigilance (PV)
AGRICULTURAL & VETERINARY CHEMICALS REGULATION IN AUSTRALIA
EPRUMA – Part of Responsible Use Declan O’ Brien on behalf of EPRUMA TAIEX, Istanbul, April 19th, 2011.
Future Innovation in Animal Diagnostics
Pharmacovigilance & Adverse Drug Reactions Dr. Habab Khalid Elkheir
Pharmacovigilance Systems: Drug Safety Surveillance
Evaluation of immunogenicity Case presentations CEMDC-PharmaTrain, Module 8. Budapest, Hungary, 12-May-2017 Vid Stanulovic MD, PhD Clinical pharmacologist,
Equine Euthanasia and Disposal Challenges
Patient Involvement in the Development and Safe Use of
Pharmacovigilance updates
Tobey Clark, Director*, Burlington USA
A Real World Application of the Scientific Method
Prescription-only vs. over-the-counter medicines
Workshop From petri dish to population - and back again
All Professionals are involved in
PHARMACOVIGILANCE SYSTEM
Interconnection of good practices: from development to distribution
Presentation transcript:

The Role of the Private Vet Pharmacovigilance: The Role of the Private Vet Istanbul April 2011 Dr Joe Collins MVB PhD CBiol FSB MRCVS CertEP CertVR

Who Participates in Pharmacovigilance?

WHAT IS PHARMACOVIGILANCE? Evaluating quality, safety and efficacy of veterinary medicines in practical use situations Using these findings in product availability and literature in order to Maximise animal health, welfare and public health The combined efforts of: Authorities Industry Animal owners/keepers Private Veterinary Practice Vets Vet nurses Staff

Working Dogs! Fat Dogs! Fat Dogs! Old Dogs! Pre-Disposed Breeds!

Private Vet Pharmacovigilance System- Initial Recognition Regulatory Authority Private Vet End user Pharma Sales Force Pharma Veterinary Services

Adverse Drug Reaction A 'reaction in human or animal to a VMP which is noxious and unintended and which occurs after the use of, or exposure to, a veterinary medicinal product, whether on or off-label'.

WHY DO WE NEED PHARMACOVIGILANCE? Limitations of pre-marketing drug trials: Many are non-clinical studies Tight focus: Short Duration Narrow Population Narrow set of indications Small size Trials seldom detect or define the frequency of all important adverse reactions

Limitations of Reported Pharmacovigilance Length of time product has been on the market – newness -increased reporting rate in the first 2 years Temporal reporting biases –recently treated -reactions within 4 weeks of treatment Reporting environment - topical -media coverage Individual biases - subjective -reporter is ‘convinced’ product is responsible or not effective

LIMITATIONS OF PHARMACOVIGILANCE

Report Types Suspect Adverse Drug Reaction (Human and Animal)–SSADR & SADR Suspect Lack of Expected Efficacy – SLEE MRL violations Environmental issues

Accidental Self-Administration

Palatability

Injection - Drench - Pour-On

PVP Issues with PV Reporting Funding of diagnostic tests / referral examinations Return product analysis Company Veterinary opinion Complaint resolution Communication with owner, industry, RA

Essentials of a PV Report REPORTER IDENTIFICATION ANIMAL DATA PRODUCT DATA SUSPECTED ADVERSE REACTION

THANNKS FOR YOUR ATTENTION